Related references
Note: Only part of the references are listed.Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
Dilana Staudt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
Mark J. Levis et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays
Sabah Kadri et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Leukemogenic potency of the novel FLT3-N676K mutant
Kezhi Huang et al.
ANNALS OF HEMATOLOGY (2016)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes
E. J. Duncavage et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
Amplicon Indel Hunter Is a Novel Bioinformatics Tool to Detect Large Somatic Insertion/Deletion Mutations in Amplicon-Based Next-Generation Sequencing Data
Sabah Kadri et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine
N. Chatain et al.
LEUKEMIA (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
Jean-Emmanuel Bibault et al.
ONCOTARGET (2015)
Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia
Mark Levis
FUTURE ONCOLOGY (2014)
Acute myeloid leukemia: 2013 update on risk-stratification and management
Elihu H. Estey
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, Next-Generation Sequencing Data
David H. Spencer et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
Mark Levis
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
Susanne Schnittger et al.
GENES CHROMOSOMES & CANCER (2012)
Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations
Felicitas Thol et al.
GENES CHROMOSOMES & CANCER (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells
Weina Chen et al.
MOLECULAR CANCER (2010)
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor
Frank Breitenbuecher et al.
BLOOD (2009)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML
C Reindl et al.
BLOOD (2006)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay
KM Murphy et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
Genomic structure of human FLT3:: Implications for mutational analysis
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
